Article
To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.
European journal of haematology - 1 Oct 2026
Martino Enrica Antonia, Caserta Santino, Vigna Ernesto, Cutrona Giovanna, Bruzzese Antonella, Mendicino Francesco, Alvaro Maria Eugenia, Labanca Caterina, Lucia Eugenio, Olivito Virginia, Amodio Nicola, Fais Franco, Neri Antonino, Ferrarini Manlio, Gattei Valter, Morabito Fortunato, Gentile Massimo
Abstract excerpt
Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch-and-wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment. Over the past two decades, however, substantial advances in genomic profiling-including immunoglobulin heavy-chain variable region (IGHV) mutational...
Read the complete abstract on PubMedTopics
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
- Molecular Targeted Therapy
- Prognosis